Monika Brüggemann, MD, PhD

University of Schleswig-Holstein, Campus Kiel, Germany

Poster(s):

• 1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial